HOME / RESEARCH COMPOUNDS / BPC-157
Lyophilised vial · supplied for laboratory research
BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids (GEPPPGKPADDAGLV). Researchers at the University of Zagreb described it in 1993 as a partial sequence of "body protection compound", a larger protein they reported in human gastric juice. The material used in research is made by solid-phase peptide synthesis, not extracted.
Titan Peptides supplies BPC-157 as a lyophilised powder in a sealed 10 mg vial for laboratory research only. It is not a medicine and is not for human or veterinary use. The research summary below sets out what has been studied, in which models, and how the peptide is treated under Australian law and in sport.
| Compound class | Synthetic linear peptide (pentadecapeptide, 15 residues) |
|---|---|
| Sequence (one-letter) | GEPPPGKPADDAGLV |
| Sequence (three-letter) | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular formula | C62H98N16O22 (free peptide, PubChem) |
| Molar mass | 1419.5 g/mol (free peptide, PubChem) |
| CAS number | 137525-51-0 |
| PubChem CID | 9941957 |
| Other names | PL 14736, PLD-116, PL-10, bepecin |
| Supplied as | Lyophilised powder, sealed vial |
| Strength | 10 mg per vial |
| Storage (lyophilised) | Sealed, dry and dark at −20 °C or colder; −50 to −80 °C for long-term storage |
| Intended use | Laboratory research only |
The BPC-157 literature is large but narrow in type. A 2025 systematic review screened 544 records published from 1993 to 2024 and included 36 studies of mechanism, musculoskeletal outcomes, metabolism and safety: 35 were preclinical and one was clinical.1 Our BPC-157 research overview goes through the main studies in detail. The themes are:
BPC-157 is often discussed alongside TB-500, an unrelated fragment of thymosin beta-4. BPC-157 vs TB-500 compared sets out how the two differ in structure, proposed mechanism and evidence.
In Australia, BPC-157 is listed in Schedule 4 (Prescription Only Medicine) of the Poisons Standard June 2026 (F2026L00633) and in Appendix D, clause 5, which covers poisons that must not be possessed without authority, such as a legal prescription.6 The TGA's safety advisory of 13 April 2026 names BPC-157 as an example of an unapproved peptide product and states that a "research use only" disclaimer does not make its supply lawful.7 In sport, the 2026 WADA Prohibited List names BPC-157 in class S0, non-approved substances, prohibited at all times.8
BPC-157 is not an approved medicine in Australia or the United States; the vial sold here is a research chemical. Our guide to research peptides and Australian law explains how scheduling applies.
Keep the sealed vial dry, dark and frozen at −20 °C or colder, and colder still (−50 to −80 °C) for long-term storage. Let it reach room temperature in a desiccator before opening, so moisture does not condense on the hygroscopic powder. The sequence has none of the cysteine, methionine or tryptophan residues most prone to oxidation, nor the asparagine or glutamine residues prone to deamidation, but solutions are still short-lived: split a reconstituted stock into single-use aliquots, freeze them, and discard a thawed aliquot rather than refreezing it. See how to store peptides and reconstituting peptides with bacteriostatic or sterile water for the reasoning behind each step.
BPC-157 is supplied as a lyophilised (freeze-dried) powder in a sealed vial containing 10 mg, for laboratory research only. Peptides are often supplied as salts, and PubChem also records a trifluoroacetate form of BPC-157, so documentation for a salt form can list a different formula and mass from the free-peptide values of C62H98N16O22 and 1419.5 g/mol.
The CAS number for BPC-157 is 137525-51-0, and its PubChem compound ID is 9941957. The same peptide appears in the literature as PL 14736, PLD-116, PL-10 and bepecin; a 2003 paper noted that it was then in clinical trials for inflammatory bowel disease under the Pliva codes PL 14736 and PLD-116.
BPC-157 is a Schedule 4 substance in the June 2026 Poisons Standard and is also listed in Appendix D, clause 5, which covers poisons that must not be possessed without authority, such as a legal prescription. The TGA names it as an unapproved peptide product and says a research-use-only label does not make supply lawful. States and territories implement scheduling through their own legislation.
They are unrelated molecules. BPC-157 is a 15-residue fragment of a gastric juice protein; TB-500 is a synthetic, N-acetylated seven-residue fragment of thymosin beta-4 (Ac-LKKTETQ). Their proposed mechanisms in laboratory models differ, their molar masses differ by about 530 g/mol, and no study has compared the two head to head.
No randomised controlled trial of BPC-157 has been published. The human data are three small pilot reports of two to 16 people, none with a control group. A phase I study of an oral tablet, registered in 2015, lists its status as unknown and has posted no results. A 2025 systematic review found no clinical safety data.
A plain-English review of the BPC-157 literature: where the peptide came from, what animal and cell studies reported, why human evidence is so thin, and where it sits under Australian scheduling and anti-doping rules.
Two peptides that are often mentioned together but have nothing structurally in common. A side-by-side look at where BPC-157 and TB-500 come from, what studies reported, and where each sits under Australian and WADA rules.
TB-500 and thymosin beta-4 are not the same molecule. This overview explains the fragment, the full-length protein most studies used, the thin human data, and the Australian and WADA position.
A section-by-section guide to reading a peptide certificate of analysis: identity, HPLC purity, net peptide content, counter-ions, water, endotoxin, and the red flags that mean a COA does not check out.
All products are supplied strictly for laboratory research and in-vitro applications. They are not approved therapeutic goods in Australia and are not for human or veterinary use.
